Northern Alberta Psychosocial Telecare (NAPT) Screening for HNC Patients (NAPT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03215199 |
Recruitment Status :
Recruiting
First Posted : July 12, 2017
Last Update Posted : July 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer Distress | Other: NAPT | Not Applicable |
This is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients.
This study will utilize a web-based application available on desktop or laptop computers, and smartphones. The application involves monitoring using the NCCN Distress Thermometer Score, the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) score, and the Head and Neck Research Network (HNRN-33), a patient-reported, validated functional outcomes score. These assessments will be completed at baseline, 2 weeks postoperatively, and monthly thereafter until 12 months. Patients will have the option of filling out questionnaires more frequently if desired.
This web-based application, the NAPT App, will allow patients to alert the treatment team of their current state of mood or distress. Automatic alerts will be sent to the team if a Distress Score of </=3, a QIDS score >/=11, or suicidal ideation are expressed in the application.
The study duration will be 12 months with a primary endpoint of 6 months. Our primary outcome will be NCCN Distress Thermometer Score at 6 months, with secondary outcomes of the QIDS and HNRN-33 functional scores at 6 and 12 months. Additional outcomes assessed will pertain to completion of adjuvant therapy, weight maintenance, rehabilitation and return to work, and survival. Health services delivery outcomes, such as primary care visits, emergency department visits, hospitalizations, and narcotic use will also be evaluated.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Northern Alberta Psychosocial Telecare (NAPT) Screening for Surgical Head and Neck Cancer Patients: a Randomized Controlled Trial |
Actual Study Start Date : | September 1, 2017 |
Estimated Primary Completion Date : | June 13, 2023 |
Estimated Study Completion Date : | June 13, 2023 |
Arm | Intervention/treatment |
---|---|
No Intervention: Usual Care Group
The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
|
|
Active Comparator: NAPT Group
The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
|
Other: NAPT
Web-based depression and distress monitoring application |
- Distress Thermometer Score [ Time Frame: 6 months ]NCCN Distress Thermometer Score
- QIDS Score [ Time Frame: 6 and 12 months ]Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR)
- HNRN-33 [ Time Frame: 6 and 12 months ]Head and Neck Research Network (HNRN-33)
- Completion of Adjuvant Therapy [ Time Frame: 6 months ]Completion of Adjuvant Therapy, including radiation or chemotherapy
- Return to work [ Time Frame: 12 months ]Return to work by 12 months
- Hospital Readmissions [ Time Frame: 12 months ]Hospital Readmissions
- Primary Care Visits [ Time Frame: 12 months ]Primary Care Visits to Family Physician
- Emergency Department Visits [ Time Frame: 12 months ]Emergency Department Visits

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years
- New (non-recurrent) head and neck cancer
- Primary surgical treatment
Exclusion Criteria:
- <18 years
- Recurrent head and neck cancer
- Previous chemotherapy or radiation therapy
- History of psychiatric or psychologic illness
- History of previous cancers or cancer distress

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03215199
Contact: Brittany Barber | 6464459592 | brittanybarber0@gmail.com | |
Contact: Scott Murray | sipmurray@gmail.com |
Canada, Alberta | |
University of Alberta | Recruiting |
Edmonton, Alberta, Canada, T6G 2B7 | |
Contact: Brittany Barber, MD 16464459592 brittanybarber0@gmail.com | |
Contact: Scott Murray, MD sipmurray@gmail.com |
Responsible Party: | University of Alberta |
ClinicalTrials.gov Identifier: | NCT03215199 |
Other Study ID Numbers: |
HREBA.CC-17-0160 |
First Posted: | July 12, 2017 Key Record Dates |
Last Update Posted: | July 13, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |